ABX464 is primarily investigated for its potential in treating inflammatory diseases and viral infections, particularly HIV. It functions by modulating RNA splicing and promoting the production of anti-inflammatory molecules. In HIV treatment, ABX464 has shown ability to reduce the viral reservoir, which is critical for achieving long-term remission or a functional cure. It enhances the elimination of integrated HIV RNA from infected cells, supporting its role in latency reversal and viral clearance. Additionally, ABX464 is being explored in clinical trials for ulcerative colitis due to its strong anti-inflammatory effects in the gastrointestinal tract. Its unique mechanism of action makes it a promising candidate for diseases where conventional therapies are limited.